Replies to post #36616 on Relief Therapeutics Holding AG (RLFTF)

[J-Belfort]

The significance of the reduction in LOS (length of stay) in the paper is extremely important

This is the metric Remdisivar was granted a EUA based upon. Not only is the difference in reduction seen with Zyesami greater, it is shown with a far higher degree of confidence.
About 1 in 2000 probability it was a random occurrence. Far exceeding the 5 in 100 gold standard.

"The median time in hospital was similarly analyzed by Cox proportional hazards model. A 10 day median difference in time to hospital length of stay was seen in all HFNC participants (P=.006) and a 13 day difference was seen in those treated in tertiary care centers (P=.004). "